drugset / Trial / NCT03229746

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

NCT03229746

Phase 4 Completed 40 enrolled Assiut University
RandomizedParallel-groupOpen-labelTreatment

Summary

Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect. Immune thrombocytopenia (ITP) is known as an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet count. However, refractory ITP is lacking of effective treatments and the efficacy of decitabine in ITP remains poorly understood. Data from this study may provide some idea of Hydroxychloroquine in the treatment of ITP in comparison to other lines of treatment as detected by the standardized definitions.

Timeline

Start
2017-08-01
Primary completion
2018-06-01
Completion
2018-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 100 mg
Subject Hydroxychloroquine Small molecule 200 mg Oral
Comparator Vincristine Small molecule 1 mg Intravenous